Governing Biotechnology
By George Annas,
Global Agenda Magazine
| 02. 13. 2006
Developments in biotechnology have made possible species-changing and even species-endangering procedures, says George Annas. We urgently need a global governance structure to regulate them.
Albert Einstein cogently observed that "imagination is more important than knowledge." He could have gone further. Moral imagination is more important than scientific imagination. The unmet challenge for science at the beginning of the 21st century is to develop a global bioethics governance system that can help to ensure that biomedical technology enhances human life, and does not degrade or end it.
Paradoxically, the global biotechnology research agenda is facing backwards and forwards at the same time. Looking back, we are trying to react to threats of global pandemics, bioterrorism, and biowarfare. Looking forwards, we are striving to use new biomedical technologies not only to cure or prevent disease but also to physically modify humans in ways that could change our concept of humanity.
So far the world is taking governance of backward-looking technologies more seriously than the forward-looking ones. This is probably because the world has had lots of experience of pandemics and war, because...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...